These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 37026714)

  • 41. Sotatercept for Pulmonary Arterial Hypertension in the Inpatient Setting.
    Torbic H; Tonelli AR
    J Cardiovasc Pharmacol Ther; 2024; 29():10742484231225310. PubMed ID: 38361351
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neuroblastoma Suppressor of Tumorigenicity 1 Mediates Endothelial-to-Mesenchymal Transition in Pulmonary Arterial Hypertension Related to Congenital Heart Disease.
    Wen B; Peng R; Kong P; Li Z; Liu Y; Ouyang W; Xie Y; Hu X; Wang Q; Pan X
    Am J Respir Cell Mol Biol; 2022 Dec; 67(6):666-679. PubMed ID: 36169661
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Role of Bone Morphogenetic Protein Receptor Type 2 (
    Devendran A; Kar S; Bailey R; Trivieri MG
    Cells; 2022 Nov; 11(23):. PubMed ID: 36497082
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibition of overactive transforming growth factor-β signaling by prostacyclin analogs in pulmonary arterial hypertension.
    Ogo T; Chowdhury HM; Yang J; Long L; Li X; Torres Cleuren YN; Morrell NW; Schermuly RT; Trembath RC; Nasim MT
    Am J Respir Cell Mol Biol; 2013 Jun; 48(6):733-41. PubMed ID: 23418342
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapeutic Monoclonal Antibody Antagonizing Endothelin Receptor A for Pulmonary Arterial Hypertension.
    Zhang C; Wang X; Zhang H; Yao C; Pan H; Guo Y; Fan K; Jing S
    J Pharmacol Exp Ther; 2019 Jul; 370(1):54-61. PubMed ID: 30992315
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A critical role for Egr-1 during vascular remodelling in pulmonary arterial hypertension.
    Dickinson MG; Kowalski PS; Bartelds B; Borgdorff MA; van der Feen D; Sietsma H; Molema G; Kamps JA; Berger RM
    Cardiovasc Res; 2014 Sep; 103(4):573-84. PubMed ID: 25028387
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bone Morphogenetic Protein 9 Is a Mechanistic Biomarker of Portopulmonary Hypertension.
    Nikolic I; Yung LM; Yang P; Malhotra R; Paskin-Flerlage SD; Dinter T; Bocobo GA; Tumelty KE; Faugno AJ; Troncone L; McNeil ME; Huang X; Coser KR; Lai CSC; Upton PD; Goumans MJ; Zamanian RT; Elliott CG; Lee A; Zheng W; Berasi SP; Huard C; Morrell NW; Chung RT; Channick RW; Roberts KE; Yu PB
    Am J Respir Crit Care Med; 2019 Apr; 199(7):891-902. PubMed ID: 30312106
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Promising therapeutic approaches in pulmonary arterial hypertension.
    Ali MK; Ichimura K; Spiekerkoetter E
    Curr Opin Pharmacol; 2021 Aug; 59():127-139. PubMed ID: 34217109
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prostaglandin and prostaglandin receptors: present and future promising therapeutic targets for pulmonary arterial hypertension.
    Zeng C; Liu J; Zheng X; Hu X; He Y
    Respir Res; 2023 Nov; 24(1):263. PubMed ID: 37915044
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Platelet-Derived TGF (Transforming Growth Factor)-β1 Enhances the Aerobic Glycolysis of Pulmonary Arterial Smooth Muscle Cells by PKM2 (Pyruvate Kinase Muscle Isoform 2) Upregulation.
    Zhu Y; Shu D; Gong X; Lu M; Feng Q; Zeng XB; Zhang H; Gao J; Guo YW; Liu L; Ma R; Zhu L; Hu Q; Ming ZY
    Hypertension; 2022 May; 79(5):932-945. PubMed ID: 35232222
    [TBL] [Abstract][Full Text] [Related]  

  • 51. From bones to blood pressure, developing novel biologic approaches targeting the osteoprotegein pathway for pulmonary vascular disease.
    Dawson S; Lawrie A
    Pharmacol Ther; 2017 Jan; 169():78-82. PubMed ID: 27373854
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Injury-Induced Shedding of Extracellular Vesicles Depletes Endothelial Cells of Cav-1 (Caveolin-1) and Enables TGF-β (Transforming Growth Factor-β)-Dependent Pulmonary Arterial Hypertension.
    Oliveira SDS; Chen J; Castellon M; Mao M; Raj JU; Comhair S; Erzurum S; Silva CLM; Machado RF; Bonini MG; Minshall RD
    Arterioscler Thromb Vasc Biol; 2019 Jun; 39(6):1191-1202. PubMed ID: 30943774
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nutraceuticals in the Treatment of Pulmonary Arterial Hypertension.
    Sánchez-Gloria JL; Osorio-Alonso H; Arellano-Buendía AS; Carbó R; Hernández-Díazcouder A; Guzmán-Martín CA; Rubio-Gayosso I; Sánchez-Muñoz F
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32650586
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology.
    Meloche J; Courchesne A; Barrier M; Carter S; Bisserier M; Paulin R; Lauzon-Joset JF; Breuils-Bonnet S; Tremblay É; Biardel S; Racine C; Courture C; Bonnet P; Majka SM; Deshaies Y; Picard F; Provencher S; Bonnet S
    J Am Heart Assoc; 2013 Jan; 2(1):e005157. PubMed ID: 23525442
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BMPRII deficiency impairs apoptosis via the BMPRII-ALK1-BclX-mediated pathway in pulmonary arterial hypertension.
    Chowdhury HM; Sharmin N; Yuzbasioglu Baran M; Long L; Morrell NW; Trembath RC; Nasim MT
    Hum Mol Genet; 2019 Jul; 28(13):2161-2173. PubMed ID: 30809644
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Haemodynamic effects of PAH-targeted therapies in pulmonary hypertension due to lung disease: A systematic review and meta-analysis.
    Farmakis IT; Vazakidis P; Doundoulakis I; Arvanitaki A; Zafeiropoulos S; Boutou A; Karvounis H; Giannakoulas G
    Pulm Pharmacol Ther; 2021 Jun; 68():102036. PubMed ID: 33979684
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sotatercept for the Treatment of Pulmonary Arterial Hypertension.
    Humbert M; McLaughlin V; Gibbs JSR; Gomberg-Maitland M; Hoeper MM; Preston IR; Souza R; Waxman A; Escribano Subias P; Feldman J; Meyer G; Montani D; Olsson KM; Manimaran S; Barnes J; Linde PG; de Oliveira Pena J; Badesch DB;
    N Engl J Med; 2021 Apr; 384(13):1204-1215. PubMed ID: 33789009
    [TBL] [Abstract][Full Text] [Related]  

  • 58. NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension.
    Mulvaney EP; Reid HM; Bialesova L; Bouchard A; Salvail D; Kinsella BT
    BMC Pulm Med; 2020 Apr; 20(1):85. PubMed ID: 32252727
    [TBL] [Abstract][Full Text] [Related]  

  • 59. RAGE-mediated extracellular matrix proteins accumulation exacerbates HySu-induced pulmonary hypertension.
    Jia D; He Y; Zhu Q; Liu H; Zuo C; Chen G; Yu Y; Lu A
    Cardiovasc Res; 2017 May; 113(6):586-597. PubMed ID: 28407046
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Loss of SMAD3 Promotes Vascular Remodeling in Pulmonary Arterial Hypertension via MRTF Disinhibition.
    Zabini D; Granton E; Hu Y; Miranda MZ; Weichelt U; Breuils Bonnet S; Bonnet S; Morrell NW; Connelly KA; Provencher S; Ghanim B; Klepetko W; Olschewski A; Kapus A; Kuebler WM
    Am J Respir Crit Care Med; 2018 Jan; 197(2):244-260. PubMed ID: 29095649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.